zolgensma fda disclosur unlik benefit
yesterday novarti indic june compani self-disclos
fda health author eu japan data previous
submit bla packag inaccur specif
alleg data manipul specif anim test procedur use
develop product compani also highlight data
question small portion overal submiss limit
older process longer use colleagu team
cover call novarti perspect provid
commentari summari perspect
believ disclosur novarti provid competit relief
spinraza franchis inde think zolgensma risdiplam
impact sale trajectori spinraza outlin note interact
sma market model reiter under-perform tp
risdiplam like larger threat biogen sma franchis zolgensma
impact incid market continu believ roche/ptc
risdiplam could much pronounc impact biogen sma
franchis current assum earli risdiplam could take
share across sma type preval market continu
forecast zolgensma take major share newli type incid
market spinraza estim factset con
increas continu maintain consensu
estim fulli account competit threat pose risdiplam
beyond sma headwind ms franchis mount near-
term see risk tecfidera on-going legal uspto challeng
product ip note hear ipr schedul
nov anoth separ court case schedul begin earli dec
note potenti outcom mylan tecfidera ipr
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater expect rate new therapi take greater
expect share near-term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
follow disclosur novarti manag host confer call ceo
